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Abstract The neuroprotective e¡ects of lithium, a mood stabi-
lizer, against glutamate-induced excitotoxicity in rat cortical
neurons were associated with a decrease in Tyr1472 phosphor-
ylation of the N-methyl-D-aspartate (NMDA) receptor NR2B
subunit and a loss of receptor activity. Since this receptor tyro-
sine phosphorylation is mediated by the Src-family tyrosine ki-
nases, we investigated the e¡ects of lithium on the Src kinase
activity. Levels of phosphorylated Src kinase at Tyr416, an
index of Src activation, were reduced after treatment with
LiCl (1 mM) for more than 3 days. Protein levels of Src-family
kinases such as Src, Fyn, and Yes were unchanged by lithium
treatment. The activities of cytosolic protein tyrosine kinase and
protein phosphatase were also unchanged by lithium treatment,
indicating the selectivity and the modulation. Moreover, the
levels of postsynaptic densities (PSD) and SynGAP, the scaf-
folding proteins of the NMDA receptor complex, were unaltered
by lithium. A Src kinase inhibitor, SU6656, and an NR2B an-
tagonist, ifenprodil, partially blocked glutamate excitotoxicity.
Our results suggest that lithium-induced inactivation of Src ki-
nase contributes to this drug-induced NMDA receptor inhibition
and neuroprotection against excitotoxicity.
6 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Protein phosphorylation by the Src-family tyrosine kinases
has been implicated in the regulation of a variety of cellular
functions [1]. One of the prominent substrates of the Src-fam-
ily kinases is the N-methyl-D-aspartate (NMDA) receptor,
which plays a central role in neuronal development, synaptic
plasticity and excitotoxicity. Src-family kinases bind to scaf-
folding proteins in the NMDA receptor complex [2]. Tyrosine
phosphorylation of the NMDA receptor subunits, NR2A and
NR2B, by Src-family kinases such as Src and Fyn, results in
enhancement of receptor activity [3,4]. NR2B Tyr1472 is one
of the sites phosphorylated by Src and Fyn kinases [5,6] and
its tyrosine mutation causes a loss of stimulus-induced calci-
um in£ux through the NMDA receptor channel [7]. Although
the function of Src-family kinases in the central nervous sys-
tem is becoming clear, their regulation of activity is still
largely elusive.
Lithium has long been a primary drug used for the treat-
ment and prophylaxis of bipolar mood disorder; however, its
therapeutic mechanisms remain unclear. Recently, this drug
was found to have robust neuroprotective e¡ects against a
variety of insults including excitotoxicity in vitro and in
vivo [8,9]. We have reported that long-term, but not acute
lithium treatment induces a selective decrease in the level of
NR2B Tyr1472 phosphorylation in rat cerebral cortical neu-
rons [10]. This lithium-induced e¡ect is correlated with a loss
of glutamate-stimulated NMDA receptor activity and with its
neuroprotection against NMDA receptor-mediated excitotox-
icity [10,11]. Since phospho-tyrosine levels associated with
NMDA receptors could be regulated by both tyrosine protein
kinase and tyrosine protein phosphatase, this study was
undertaken to examine the e¡ects of lithium on the activities
of these enzymes with a particular emphasis on the Src-family
kinases.
2. Materials and methods
2.1. Animals and chemicals
All procedures employing experimental rats were performed in
compliance with the National Institutes of Health guidelines for the
care and use of laboratory animals.
2.2. Primary cultures of rat cerebral cortical neurons and
drug treatments
Primary cultures of rat cerebral cortical neurons were prepared
from 17-day-old embryonic rats cultured as described previously
[12]. Cells were plated at a density of 4.2U105 cells/cm2 on polyeth-
yleneimine-precoated 96-well plates or 6-well plates. Cultures were
maintained in serum-free B27/Neurobasal medium (Life Technologies,
Rockville, MD, USA). Over 95% of the cells present on day 5 in vitro
were di¡erentiated into neurons, as characterized by the appearance
of long neurites expressing neuro¢lament protein [13]. Routinely, cor-
tical neurons on day 9 in vitro were treated with 1 mM LiCl and
maintained for an additional 5 days in culture. Glutamate (8 WM)
was then added to the culture medium on day 15 in vitro and cell
viability was determined 24 h later.
2.3. Measurement of neurotoxicity
Cortical neuronal cultures were plated on 96-well plates and main-
tained for 16 days. Viability of cortical neurons was determined by the
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay, which detects mitochondrial dehydrogenase activity, as de-
scribed previously [14]. Neuroprotection is expressed as a percentage
of maximal neuroprotection, using values derived from glutamate-
treated cells and the untreated control as a reference. One-way AN-
OVA was used for the statistical analysis, and signi¢cant di¡erences in
cell viability were determined by post-hoc comparisons of means using
Bonferroni’s post-hoc test.
2.4. Western blotting
Cells were lysed with sodium dodecyl sulfate (SDS) bu¡er (50 mM
Tris^HCl, pH 7.5, 0.5% SDS, 1 mM dithiothreitol). The lysates were
sonicated at 30 amplitudes (SonicpMaterials, Danbury, CT, USA) in
an ice-bath four times, for 10 s each time, and then an aliquot of 50
Wg protein was dissolved in the sample bu¡er for SDS^polyacrylamide
gel electrophoresis and Western blotting as described previously [15].
Separated proteins were transferred onto a polyvinylidene di£uoride
membrane, which was incubated with a primary antibody against Src
(monoclonal; Oncogene, San Diego, CA, USA), Fyn (polyclonal;
Santa Cruz, Santa Cruz, CA, USA), c-Yes (monoclonal; Wako
Chemicals, Richmond, VA, USA), phospho-Src (polyclonal against
phospho-Tyr416; Cell Signaling Technology, Beverly, MA, USA),
postsynaptic density (PSD)-95 (monoclonal; Upstate, Lake Placid,
NY, USA) or SynGAP (polyclonal; Upstate). Membranes were
washed and then exposed to the secondary antibody, horseradish per-
oxidase-conjugated anti-mouse or anti-rabbit IgG (Amersham Phar-
macia Biotech, Arlington Heights, IL, USA). Immunoreactive protein
bands were visualized by ECL detection and quanti¢ed using a CCD
camera (Sierra Scienti¢c, Sunnyvale, CA, USA) and Macintosh NIH
Image 1.6 software. Statistical di¡erences between untreated and lith-
ium-treated samples were analyzed by Student’s t-test. The detection
limits were 10 Wg protein of lysates from samples of untreated cells for
phospho-Src, total Fyn and Yes, and 2 Wg protein for total Src, PSD-
95 and SynGAP. The coe⁄cients of variation (determined by stan-
dard deviation/mean) in untreated controls and lithium-treated sam-
ples were 9.3% and 11.5% for phospho-Src, 8.3% and 6.2% for total
Src, 9.5% and 9.9% for total Fyn, 10.2% and 11.2% for total Yes,
7.6% and 7.3% for PSD-95, and 8.1% and 9.7% for SynGAP, respec-
tively.
2.5. Protein tyrosine kinase activity assay
The tyrosine kinase activity of cortical primary culture cells was
measured using the SignaTECT Protein Tyrosine Kinase Assay Sys-
tem (Promega, Madison, WI, USA), according to the manufacturer’s
instructions. Brie£y, cultured cells were solubilized on ice using pro-
tein tyrosine kinase (PTK) extraction bu¡er. The lysates were centri-
fuged at 10 000Ug and the supernatants were collected. An aliquot of
5 Wl containing 2 Wg cytosolic protein from each sample was then
incubated for 15 min at 30‡C in 20 Wl of PTK reaction bu¡er con-
taining 8 mM imidazole hydrochloride (pH 7.3), 8 mM L-glycerophos-
phate, 0.2 mM ethylene glycol-bis(2-aminoethyl-ether)-N,N,NP,NP-tet-
raacetic acid, 20 mM MgCl2, 1 mM MnCl2, 0.1 mg/ml bovine serum
albumin, 1 mM Na3VO4, 25 WM ATP, 25 WCi/ml [Q-32P]ATP (3000
Ci/mmol) (NEN, Boston, MA, USA), and 0.3 mM PTK biotinylated
peptide substrate as a substrate. Several concentration-dependent ex-
periments were performed to ensure that this amount of cytosolic
protein (2 Wg) was within the linear range of the PTK assay. Increas-
ing or decreasing the pH value from 7.3 did not enhance the activities
of PTK. The reaction was terminated by addition of 12.5 Wl of 7.5 M
guanidine hydrochloride. An aliquot of 12.5 Wl of each sample was
spotted onto a SAM2 biotin capture membrane. These membranes
were washed with 2 M NaCl, then with 2 M NaCl in 1% H3PO4.
The incorporated 32P radioactivity was then quanti¢ed and the en-
zyme-speci¢c activity was determined.
2.6. Protein tyrosine phosphatase activity assay
The tyrosine phosphatase activity of cortical primary culture cells
was measured using the SignaTECT Protein Tyrosine Phosphatase
Assay System (Promega), according to the manufacturer’s instruc-
tions. Brie£y, cultured cells were solubilized on ice using protein ty-
rosine phosphatase (PTP) extraction bu¡er. The endogenous phos-
phate was removed from the 10 000Ug supernatant using a
Sephadex G-25 column. An aliquot of 5 Wl containing 2 Wg cytosolic
protein from each sample was then incubated for 15 min at 30‡C in 50
Wl of reaction bu¡er containing 10 mM Tris^HCl, pH 7.3, and 100
WM of tyrosine-phosphopeptide as a substrate in 96-well microtiter
plates. Several concentration-dependent experiments were performed
to ensure that this amount of cytosolic protein (2 Wg) was within the
linear range of the PTP assay. Increasing or decreasing the pH value
from 7.3 did not enhance the activities of PTP. The reaction was
terminated by addition of 50 Wl of molybdate dye/additive mixture.
After the mixture was incubated at room temperature for 15 min,
optical density of the samples was measured using a plate reader at
a wavelength of 630 nm, and the PTP activity was calculated.
2.7. Protein determination and statistical analysis
Protein concentrations were determined by the bicinchoninic acid
kit (Pierce, New York, NY, USA), using bovine serum albumin as the
standard. One-way ANOVA was used for the statistical analysis, and
signi¢cant di¡erences in cell viability were determined by post-hoc
comparisons of means using Bonferroni’s post-hoc test.
3. Results
Cerebral cortical neurons were treated with LiCl (1 mM) on
day 9 in vitro and maintained for 5 additional days in culture.
Levels of phosphorylated Src kinase at Tyr416, an index of
Src activation, were found to be decreased by lithium treat-
ment (Fig. 1). Quanti¢cation of immunoblots revealed that
levels of phospho-Tyr416 in Src kinase were reduced to
57.3S 9.5% of the untreated control (P6 0.05). In contrast,
levels of total Src, Fyn and Yes, another member of the Src
family of kinases, were una¡ected by lithium treatment.
Moreover, levels of two NMDA receptor sca¡olding proteins,
PSD-95 [16] and SynGAP [17], were unchanged by lithium.
The lithium-induced decrease in levels of phospho-Tyr416 in
Src was time-dependent, with little or no change after treat-
ment for 10 min to 1 day, but rather showed a marked loss at
day 3 and day 5 (Fig. 2). Cytosolic tyrosine kinase activity
and tyrosine phosphatase activity, measured using PTK bio-
tinylated peptide and tyrosine-phosphopeptide as the respec-
tive substrates, were not signi¢cantly changed by pretreatment
with lithium in the concentration range of 0.2^1.0 mM (Fig.
3A,B), thus indicating the selectivity of lithium-induced Src
kinase inactivation.
Since tyrosine phosphorylation of NMDA receptors has
been linked to the activation of this receptor, we assessed its
role in glutamate-induced, NMDA receptor-mediated excito-
Fig. 1. Long-term lithium treatment decreases levels of Tyr416-phos-
phorylated Src kinase. A: Cortical cultures after 9 days in vitro
were treated with 1 mM LiCl or its vehicle for 5 days and then har-
vested for Western blotting for Tyr416-phosphorylated Src kinase,
and total protein levels of Src, Fyn, and Yes kinases as well as of
PSD-95 and SynGAP. The immunoblots done in duplicate are rep-
resentative of four independent experiments. B: Relative phospho-
Src kinase levels were obtained by normalizing to total Src kinase
levels and were expressed as percent of untreated control. Quanti¢ed
data represent meansSS.E.M. from four independent experiments.
*P6 0.05 compared with control.
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toxicity in cortical cultures. Pretreatment with SU6656 [18], a
Src kinase inhibitor, for 1 h reduced glutamate-induced exci-
totoxicity by 46.8% (Fig. 4). As expected, long-term LiCl
(1 mM) pretreatment completely blocked glutamate excitotox-
icity. Ifenprodil, an antagonist of NR2B subunits of NMDA
receptors [19], suppressed glutamate excitotoxicity by 62.3%
and MK801, a non-competitive NMDA receptor antagonist,
completely suppressed excitotoxicity (Fig. 4), indicating a
prominent role of this receptor subunit in mediating excito-
toxicity. Neither SU6656, ifenprodil, MK801 nor lithium
alone signi¢cantly a¡ected cell viability (data not shown).
4. Discussion
The present study demonstrated that long-term lithium
treatment of rat cortical neurons caused a decrease in the
activation of Src kinase, with no e¡ect on the protein levels
of Src, Fyn and Yes kinases as well as PSD-95 and SynGAP.
Moreover, neither the activity of cytosolic PTK nor that of
cytosolic PTP was a¡ected by lithium treatment, indicating
the selectivity of modulation by this drug. The relationship
of lithium-induced down-regulation of Src kinase activation
and the drug-induced decrease in NMDA receptor function
and neuroprotection against excitotoxicity is supported by the
observations that the time course of lithium-induced decrease
in Src phospho-Tyr416 levels (Fig. 1) correlated well with this
drug-induced decrease in NR2B Tyr1472 phosphorylation and
loss in NMDA receptor-mediated Ca2þ in£ux [10], and that
glutamate excitotoxicity was attenuated by the presence of
ifenprodil, an NR2B antagonist, and SU6656, a Src kinase
inhibitor (Fig. 4). To our knowledge, this is the ¢rst demon-
stration of the modulation of Src kinase activity by treatment
with a mood stabilizer. NR2B tyrosine phosphorylation is
mediated by both Src and Fyn kinases through binding to
PSD via their SH2 domains [6]. The e¡ects of lithium on
levels of activated Fyn kinase have not yet been studied
largely due to the unavailability of speci¢c antibodies for ac-
tivated, tyrosine-phosphorylated Fyn kinase. Recently, it was
reported that short-term treatment with LiCl (3 mM) in-
creases the activity of membrane-bound PTP in PC12 cells
[20]. The discrepancy between their and our results may re£ect
di¡erences in the treatment time (6 h vs. 6 days), PTP assay
(membrane-bound vs. cytosolic activity) and cell types used in
the studies.
The NMDA receptor is the primary glutamate receptor
subtype involved in excitotoxicity and neuronal death. The
ability of lithium to down-regulate Src kinase activation and
Src kinase family-mediated NR2B tyrosine phosphorylation
suggests that this drug may have additional clinical uses in
intervention of neurodegeneration. NR2B antagonists have
been shown to e¡ectively promote cell survival against exci-
totoxicity without causing complete receptor blockade, thus
reducing side e¡ects of classical NMDA receptor blockers
[21]. In this context, many NMDA receptor antagonists
were reported to partially block the devastating side e¡ects
of dyskinesia associated with L-DOPA therapy for Parkin-
son’s disease; however, NR2B selective antagonists were
found to be most e⁄cacious [22]. These observations suggest
that NR2B inhibition is a potential therapeutic strategy. Thus,
chronic lithium treatment, through inhibition of Src tyrosine
kinase-mediated NMDA receptor activation, may be bene¢-
Fig. 2. Lithium-induced decrease of Tyr416-phosphorylated Src lev-
els is time-dependent. A: Cortical cultures were treated with LiCl
(1 mM) or its vehicle for the indicated times. All cultures were har-
vested on day 14 in vitro for Western blotting for phospho-Src
(Tyr416) kinase and total Src kinase protein levels. Immunoblots
shown are representative of three independent experiments. B: Phos-
pho-Src kinase levels relative to total Src kinase protein levels.
Quanti¢ed data represent meansSS.E.M. of percent of untreated
control from three independent experiments. *P6 0.05 compared
with control.
Fig. 3. Lithium does not a¡ect levels of cytosolic PTP (A) and PTK (B) activities. Cortical cultures were treated with indicated concentrations
of LiCl or vehicle starting from day 9 in vitro and harvested on day 15 in vitro. Cytosolic proteins were prepared and activities of cytosolic
PTK and PTP were then measured. Data are meansSS.E.M. of kinase or phosphatase activities from three independent experiments.
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cial for the treatment of excitotoxicity-related neurodegenera-
tive diseases.
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Fig. 4. A Src kinase inhibitor, an NR2B receptor antagonist, long-
term lithium treatment and a non-competitive NMDA receptor
antagonist diminish glutamate-induced excitotoxicity in cortical neu-
rons. Cortical cultures were pretreated with SU6656 (0.5 WM), ifen-
prodil (5 WM) or MK801 (10 WM) for 1 h or LiCl (1 mM) for
6 days prior to exposure to glutamate (8 WM) for 24 h. Neuropro-
tection was determined using the MTT assay 24 h after glutamate
addition, as described in Section 2. Results are meansSS.E.M. of
viability measurements from ¢ve or six cultures. The viability value
of glutamate-treated cells was 60.7S 5.3% of untreated control.
**P6 0.01, ***P6 0.001 compared with glutamate alone.
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